Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $70,429.50 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Peter Kaiser sold 9,990 shares of the stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total transaction of $70,429.50. Following the sale, the insider owned 254,388 shares in the company, valued at $1,793,435.40. This represents a 3.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peter Kaiser also recently made the following trade(s):

• On Monday, August 24th, Peter Kaiser sold 3,035 shares of Ocular Therapeutix stock. The stock was sold at an average price of $10.77, for a total value of $32,686.95.

Ocular Therapeutix Price Performance

Shares of OCUL stock opened at $7.51 on Friday. The business has a fifty day simple moving average of $9.71 and a 200 day simple moving average of $9.26. The company has a market cap of $1.65 billion, a P/E ratio of -5.29 and a beta of 1.00. The company has a quick ratio of 13.03, a current ratio of 13.10 and a debt-to-equity ratio of 0.14. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. The firm had revenue of $13.47 million for the quarter, compared to analysts’ expectations of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.The business’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.39) earnings per share. On average, sell-side analysts forecast that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on OCUL shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, September 29th. Zacks Research upgraded shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Chardan Capital reiterated a “buy” rating and issued a $23.00 price target on shares of Ocular Therapeutix in a research note on Friday, October 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Ocular Therapeutix in the 2nd quarter valued at approximately $190,278,000. Commodore Capital LP bought a new stake in Ocular Therapeutix during the 1st quarter worth approximately $21,810,000. Readystate Asset Management LP bought a new stake in Ocular Therapeutix during the 1st quarter worth approximately $7,484,000. Defilade Capital Management L.P. increased its position in Ocular Therapeutix by 118.2% in the 1st quarter. Defilade Capital Management L.P. now owns 1,487,645 shares of the biopharmaceutical company’s stock valued at $12,600,000 after acquiring an additional 805,982 shares during the period. Finally, Spruce Street Capital LP acquired a new position in Ocular Therapeutix in the 4th quarter valued at approximately $9,518,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based formulation and delivery technologies to create sustained-release treatments intended to improve drug delivery, reduce dosing frequency and address unmet needs in ophthalmology.

Its commercial product is DEXTENZA, a corticosteroid ophthalmic insert that is placed in the canaliculus by a healthcare professional.